Showing 21-30 of 145 results for "".
Active Vitiligo: What to Look For
https://practicaldermatology.com/series/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.Do This Now: Be a Better Leader
https://practicaldermatology.com/topics/practice-management/do-this-now-be-a-better-leader/19111/Speaking at the Vegas Cosmetic Dermatology meeting, Todd E. Schlesinger, MD shares tips for becoming a better leader in your aesthetics practice--whether you own the practice or not. Understanding personalities and leading outside the practice walls are key.Vitiligo: Current and Future Developments
https://practicaldermatology.com/conferences/maui-derm-2020/vitiligo-current-and-future-developments/19722/John E. Harris, MD, PhD reviews treatment advances and emerging science in vitiligo. From new topical agents to intriguing studies on a potential role for biologics, there is very good reason to be optimistic about the future of vitiligo treatment.SCALE 2024: Dr. Hilary Baldwin on Benzyl Peroxide Best Practices
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwin-benzyl-peroxide-best-practices/26375/Hilary E. Baldwin, MD, provides and update on the recent issues surrounding benzyl peroxide, including a recommendation to dispose of any expired benzyl peroxide products and a discussion of proper storage, at Music City SCALE.Laser and Energy Devices Session: Dr. Ross
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/laser-and-energy-devices-session-dr-ross/32682/E. Vic Ross, MD, discusses some of the basics and applications that he covered during "Lasers and Energy Devices Used to Treat Medical Problems: What's New in 2025" at Maui Derm 2025.Dr. Ross on Therapeutic and Warning Endpoints for Laser Therapy in Skin of Color Patients
https://practicaldermatology.com/topics/skin-of-color/dr-ross-on-therapeutic-and-warning-endpoints-for-laser-therapy-in-skin-of-color-patients/28657/E. Victor Ross, MD, discusses his presentations at the Skin of Color Update, where he addressed ways to enhance using laser therapy in practice on patients with skin of color.Considerations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodHilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iCOVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, a